Chronická myeloidní leukemie
- MUDr. Daniela Žáčková, Interní hematoonkologická klinika FN Brno, Brno
- doc. MUDr. Edgar Faber, CSc., Hemato-onkologická klinika FN Olomouc
- prof. MUDr. Jiří Mayer, CSc., Interní hematoonkologická klinika FN Brno, Brno
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Otevřít | 2013 | MUDr. Vladimír Zmoraj
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
Otevřít | 2012 | MUDr. Vladimír Zmoraj
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Otevřít | 2012 | MUDr. Vladimír Zmoraj
Randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
Otevřít | 2012 | MUDr. Vladimír Zmoraj
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Otevřít | 2011 | MUDr. Vladimír Zmoraj
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Otevřít | 2011 | MUDr. Vladimír Zmoraj
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
Otevřít | 2010 | MUDr. Martina Tošková
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
Otevřít | 2010 | MUDr. Martina Tošková
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of highrisk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Otevřít | 2009 | MUDr. Alice Demovičová
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Otevřít | 2009 | MUDr. Alice Demovičová
Phase 3 study of dasatinib 140 mg once daily vs. 70 mg twice daily in patients with CML in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Dasatinib 100 mg qd daily minimizes the occurrence of pleural effusion in patients with CP-CML and efficacy is unaffected in patients who develop pleural effusion
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Transient potent bcr-abl inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Dasatinib-associated major molecular responses in patients with CML in chronic phase following imatinib failure: response dynamics and predictive value
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Acute dasatinib exposure commits bcr-abl dependent cells to apoptosis
Otevřít | 2009 | MUDr. Daniela Žáčková, dr. Marek Šťastný, PhD.
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Otevřít | 2009 | MUDr. Daniela Žáčková, MUDr. Kornelie Zahrádková
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START A trial
Otevřít | 2009 | MUDr. Markéta Vyskočilová
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Otevřít | 2008 | MUDr. František Folber
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Otevřít | 2008 | MUDr. František Folber
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or –intolerant chronic myeloid leukemia in blast crisis
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of phase 2 study
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Favorable long-term follow-up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic-phase myeloid leukemia after failure of interferon-α treatement
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Nilotinib (formely AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
Otevřít | 2008 | MUDr. Markéta Vyskočilová
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Chronic myeloid leukemia in blast crisis treated with imatinib 600mg: outcome of the patients alive after a 6-year follow-up
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Desirable performance characteristics for bcr/abl measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Nilotinib (formerly AMN 107), a highly selective bcr/abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Otevřít | 2008 | MUDr. Markéta Vyskočilová
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transkripts and kinase domain mutations and for expressing results
Otevřít | 2008 | MUDr. Markéta Vyskočilová, MUDr. Daniela Žáčková
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
Otevřít | 2007 | prof. MUDr. Jiří Mayer, CSc.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Otevřít | 2006 | MUDr. Daniela Žáčková
Evolving concepts in the management of chronic myeloid leukemia: recommendations from expert panel on behalf of the European LeukemiaNet
Otevřít | 2006 | MUDr. Markéta Vyskočilová, MUDr. Daniela Žáčková